Immunoregulatory peptides and methods of use
Assignee13 Therapeutics, Inc.
InventorsSharon L. McCoy, Steven H. Hefeneider
Life of this patent
Estimating the term…
Abstract
Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media
Claims122
1-44. (canceled)
A pharmaceutical peptide composition comprising:
- a peptide/transducing sequence conjugate, wherein the peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, or SEQ ID NO:
- 368, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus;
- and a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
A synthetic peptide of any one of:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, SEQ ID NO:
- 368, and SEQ ID NO:
- 369, conjugated to a transducing sequence at the C-terminus;
- and wherein at least one amino acid residue of the synthetic peptide is in the D-configuration.
A method of inhibiting cellular activity mediated by a toll-like receptor, the method comprising:
- administering to an organism in need thereof an effective amount of a pharmaceutical peptide composition comprising:
- a peptide/transducing sequence conjugate, wherein the peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, or SEQ ID NO:
- 368, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus;
- and a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
A method of treating inflammation in an animal, the method comprising:
- administering to an animal in need thereof a therapeutically effective amount of a pharmaceutical peptide composition comprising:
- a peptide/transducing sequence conjugate, wherein the peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, or SEQ ID NO:
- 368, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus;
- and a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
A method of treating hearing impairment in an animal, the method comprising administering a therapeutically-effective amount of a peptide composition comprising:
- a peptide/transducing sequence conjugate, wherein the peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, SEQ ID NO:
- 368, or SEQ ID NO:
- 369, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus to an animal having middle and/or inner ear inflammation and reduced hearing.
A method of treating middle and/or inner ear inflammation, the method comprising administering a therapeutically-effective amount of a peptide composition comprising:
- a peptide/transducing sequence conjugate, wherein the peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, or SEQ ID NO:
- 368, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus, to a tympanic membrane of an animal in need thereof.
A synthetic peptide/transducing sequence conjugate, wherein the synthetic peptide comprises:
- SEQ ID NO:
- 327, SEQ ID NO:
- 337, SEQ ID NO:
- 352, SEQ ID NO:
- 353, SEQ ID NO:
- 367, or SEQ ID NO:
- 368, and wherein the synthetic peptide is conjugated to the transducing sequence at the peptide C-terminus.
Dependencies are inferred from the claim text.